Original Research

Prevalence of Glaucoma in Patients With Vitiligo

Cutis. 2016 April;97(4):E21-E25

Vitiligo is an acquired idiopathic disease characterized by depigmented maculae and melanocytic destruction. We determined the prevalence of glaucoma in 49 patients who had presented to the dermatology polyclinic with vitiligo and compared that with the prevalence of glaucoma in 20 age- and sex-matched healthy controls. All patients were given an ophthalmologic examination to identify any glaucomatous changes. In the vitiligo group, 9 patients (18.4%) were found to have signs of normal-tension glaucoma (NTG), while there were no signs of NTG in the control group. This difference between the 2 groups was statistically significant (P=.04). Because glaucoma can cause permanent vision loss when left untreated, its greater prevalence among patients with vitiligo suggests that these patients should be carefully monitored.

PDF Download

Practice Points

Patients with vitiligo may exhibit pigmentary abnormalities of the iris and retina.
Normal-tension glaucoma may develop in patients with vitiligo.
Glaucoma progresses slowly and may lead to vision loss; as a result, dermatologists should be alert to the presence of glaucoma in vitiligo patients.

References

1. Ortonne JP. Vitiligo and other disorders of hypopigmentation. In: Bolognia JB, Jorizzo JL, Rapini RP, eds. Dermatology. 1st ed. New York, NY: Mosby; 2003:947-973.

2. Ortonne JP, Bahadoran P, Fitzpatrick TB, et al. Hypomelanoses and hypermelanoses. In: Freedberg IM, Eisen AZ, Wolff K, eds. Fitzpatrick’s Dermatology in General Medicine. 6th ed. New York, NY: McGraw-Hill; 2003:836-881.

3. van den Wijngaard R, Wijngaard R, Wankowiczs-Kalinsa A, et al. Autoimmune melanocyte destruction in vitiligo. Lab Invest. 2001;81:1061-1067.

4. Shields MB, Ritch R, Krupin T. Classification of the glaucomas. In: Ritch R, Shields MB, Krupin T, eds. The Glaucomas. St Louis, MO: C.V. Mosby Co; 1996:717-725.

5. Rogosić V, Bojić L, Puizina-Ivić N, et al. Vitiligo and glaucoma–an association or a coincidence? a pilot study. Acta Dermatovenerol Croat. 2010;18:21-26.

6. Anderson DR. Normal-tension glaucoma (low-tension glaucoma). Indian J Ophthalmol. 2011;59(suppl 59):S97-S101.

7. Iwata K. Primary open angle glaucoma and low tension glaucoma–pathogenesis and mechanism of optic nerve damage [in Japanese]. Nippon Ganka Gakkai Zasshi. 1992;96:1501-1531.

8. Hitchings RA, Anderton SA. A comparative study of visual field defects seen in patients with low-tension glaucoma and chronic simple glaucoma. Br J Ophthalmol. 1983;67:818-821.

9. Gopal KV, Rama Rao GR, Kumar YH, et al. Vitiligo: a part of a systemic autoimmune process. Indian J Dermatol Venereol Leprol. 2007;73:162-165.

10. Perossini M, Turio E, Perossini T, et al. Vitiligo: ocular and electrophysiological findings. G Ital Dermatol Venereol. 2010;145:141-149.

11. Biswas G, Barbhuiya JN, Biswas MC, et al. Clinical pattern of ocular manifestations in vitiligo. J Indian Med Assoc. 2003;101:478-480.

12. Park S, Albert DM, Bolognia JL. Ocular manifestations of pigmentary disorders. Dermatol Clin. 1992;10:609-622.

13. Albert DM, Nordlund JJ, Lerner AB. Ocular abnormalities occurring with vitiligo. Ophthalmology. 1979;86:1145-1160.

14. Wagoner MD, Albert DM, Lerner AB, et al. New observations on vitiligo and ocular disease. Am J Ophthalmol. 1983;96:16-26.

15. Cowan CL Jr, Halder RM, Grimes PE, et al. Ocular disturbances in vitiligo. J Am Acad Dermatol. 1986;15:17-24.

16. Orecchia GE. Neural pathogenesis. In: Hann SK, Nordlund JJ. Vitiligo. Oxford, England: Blackwell Science Ltd; 2000:142-150.

17. Braun-Falco O, Plewig G, Wolf HH, et al. Disorders of melanin pigmentation. In: Bartels V, ed. Dermatology. Berlin, Germany: Springer; 2000:1013-1042.

18. Tüzün Y, Kotoğyan A, Aydemir EH, et al. Pigmentasyon bozuklukları. In: Baransü O. Dermatoloji. 2nd ed. Istanbul: Nobel Tıp Kitabevi; 1994:557-559.

19. Odom RB, James WD, Berger TG. Disturbances of pigmentation. In: Odom RB, James WD, Berger TG. Andrews’ Diseases of the Skin. 9th ed. Philadelphia, PA: W.B. Saunders Company; 2000:1065-1068.

20. Schallreuter KU. Biochemical theory of vitiligo: a role of pteridines in pigmentation. In: Hann SK, Nordlund JJ. Vitiligo. London, England: Blackwell Science Ltd; 2000:151-159.

21. van den Wijngaard R, Wankowicz-Kalinska A, Le Poole C, et al. Local immune response in skin of generalized vitiligo patients. destruction of melanocytes is associated with the predominent presence of CLA+T cells at the perilesional site. Lab Invest. 2000;80:1299-1309.

Vitiligo is an acquired idiopathic disease of unknown etiology. Characterized by depigmented maculae and melanocytic destruction, it usually presents in childhood or young adulthood. The incidence of vitiligo ranges from 0.5% to 2% globally and there is no racial or gender predilection.¹

Patients with vitiligo may exhibit pigmentary abnormalities of the iris and retina.² Noninflammatory depigmented lesions of the ocular fundus observed in vitiligo indicate a local loss of melanocytes.¹ The fact that melanocytes are present not only in the skin and roots of the hair but also in the uvea and stria vascularis of the inner ear may explain the ophthalmologic disorders that accompany vitiligo.³ The term glaucoma refers to a large number of diseases that share a common feature: a distinctive and progressive optic neuropathy that may derive from various risks and is associated with a gradual loss of the visual field. If the disorder is not diagnosed and treated properly it could cause blindness.

Glaucoma is classified on the basis of the underlying abnormality that causes intraocular pressure (IOP) to rise. Glaucoma is first divided into open-angle and angle-closure glaucoma; glaucoma associated with developmental anomalies is then subdivided according to specific alterations.⁴

A PubMed search of articles indexed for MEDLINE using the terms vitiligo and glaucoma revealed only 1 study examining the incidence of glaucoma in patients with vitiligo.⁵ In the study reported here, we determined the presence of and possible risk factors for glaucoma in patients with vitiligo who had presented to the dermatology polyclinic.

Methods

We registered 49 patients diagnosed with vitiligo by clinical and Wood light examination and 20 age- and sex-matched healthy controls. Patients who were using topical corticosteroid treatments for vitiligo lesions located on the face were excluded from the study due to the glaucoma-inducing effects of corticosteroids. Similarly, patients who received drugs with sympathetic and parasympathetic action that can cause glaucoma were excluded.

The patients received a comprehensive ophthalmologic examination that included visual acuity testing, refraction, IOP measurement, gonioscopy, and fundus examination. All patients and controls underwent visual field tests and optic nerve head analyses using a confocal scanning laser ophthalmoscope. Glaucoma was diagnosed based on fundus examination, IOP measurement, field of vision evaluation, and optic nerve head analysis.

Informed consent was obtained from all participants. The research protocol was approved by the university hospital ethics committee.

Results

The study registered a total of 49 patients with vitiligo (28 female; 21 male) and 20 healthy controls (10 female; 10 male) with a variety of demographic and clinical characteristics (Table 1).

Mean (SD) IOP values were 13.83 (2.84) mm Hg for the right eye and 13.89 (2.60) mm Hg for the left eye in the vitiligo group. Values were 14.35 (2.56) mm Hg and 14.95 (2.92) mm Hg, respectively, in the control group. The IOP differences between the 2 groups were not statistically significant (P>.05).

Nine patients (18.4%) in the vitiligo group were found to have signs of normal-tension glaucoma (NTG). Optic nerve damage and vision loss occurs in the presence of normal IOP in NTG. There were no signs of NTG in the control group. Normal-tension glaucoma was diagnosed in the vitiligo group based on glaucomatous optic disc appearance, visual field defects, and structural analysis of the entire optic nerve head in confocal scanning laser ophthalmoscope. The NTG difference between the vitiligo and control groups was statistically significant (P=.04).

In the vitiligo group, of the 9 patients who had NTG, 6 had periorbital vitiligo lesions; the remaining 3 had none. Although patients who had periorbital lesions had a higher rate of glaucoma relative to the patients without periorbital lesions, the difference was not statistically significant (P>.05).

No statistically significant differences (P>.05) were found between patients with vitiligo with and without glaucoma in terms of age, sex, disease duration, family history of vitiligo, presence or absence of periorbital involvement, manner of involvement, percentage of the involved body areas, and IOP (Table 1).

Comment

Glaucoma is characterized by increased IOP, visual field loss, and changes in the optic nerve head. Although elevated IOP is common in ocular hypertension as well as in glaucoma, there is no glaucomatous visual field loss in ocular hypertension. In NTG, on the other hand, glaucomatous visual field loss and optic nerve head changes occur without an increase in IOP.⁶ Normal-tension glaucoma is a particular type of open-angle glaucoma. It is believed that NTG and high-tension glaucoma induce optic nerve head damage through different means.⁷ Alternative theories have been put forth to account for the glaucomatous damage to the optic nerve head that occurs in NTG, despite normal or close to normal IOP. These theories include vascular disorders (eg, ischemia, which interrupts the orthograde or retrograde axonal transport), excessive accumulation of free radicals, triggering of apoptosis, and low resistance of lamina cribrosa.⁸